Aksu Guzide, Ozturk Can, Kavakli Kaan, Genel Ferah, Kutukculer Necil
Division of Immunology, Department of Pediatrics, Ege University Medical School, 35100, Bornova-Izmir, Turkey.
Clin Rheumatol. 2007 Mar;26(3):366-70. doi: 10.1007/s10067-006-0334-y. Epub 2006 May 24.
Familial Mediterranean fever (FMF) patients in clinical remission are reported to have increased baseline inflammation. Normal function of the natural anticoagulant pathways is particularly needed in diminishing inflammatory responses. In the presence of subclinical inflammation, natural anticoagulant response may be exaggerated. We aimed to observe the anticoagulant-procoagulant status in attack-free FMF patients. Twenty-seven FMF patients diagnosed in accordance with Tel-Hashomer criteria, and 26 healthy controls were included. All patients were attack-free under regular colchicine treatment. Amyloidosis, autoimmunity, accompanying liver and renal disease, and vasculitis were excluded. Predisposing factors for thrombosis were not present. Acute phase reactants (APRs), anticardiolipin antibody positivity, prothrombin time (PT), activated prothrombin time, thrombin time (TT) and d-dimer, protein C activity, activated protein C resistance, free protein S, antithrombin, lupus anticoagulant, human prothrombin fragment F 1 + 2, and human thrombin/antithrombin III complex were analyzed for all subjects. APRs were comparable with controls. Autoimmune markers were negative in all. Anti-streptolysin titers were significantly different than the control group. PT, TT, protein C activity, and F 1 + 2 levels were significantly different from those of healthy controls. Shortened PT and TT, decreased protein C activity vs increased levels of F 1 + 2 suggested a hypercoagulable state in our patients. The hypercoagulable state detected in FMF patients suggests that screening with abnormal coagulation tests may be beneficial for tracing the future consequences of subclinical inflammation in these patients. Studies covering larger groups of patients are needed to verify the currently observed hypercoagulable status in FMF.
据报道,处于临床缓解期的家族性地中海热(FMF)患者基线炎症水平升高。在减轻炎症反应方面,天然抗凝途径的正常功能尤为必要。在亚临床炎症存在的情况下,天然抗凝反应可能会被放大。我们旨在观察无发作的FMF患者的抗凝-促凝状态。纳入了27例符合Tel-Hashomer标准诊断的FMF患者和26例健康对照。所有患者在常规秋水仙碱治疗下均无发作。排除了淀粉样变性、自身免疫、伴发的肝脏和肾脏疾病以及血管炎。不存在血栓形成的诱发因素。对所有受试者分析了急性期反应物(APR)、抗心磷脂抗体阳性率、凝血酶原时间(PT)、活化凝血酶原时间、凝血酶时间(TT)和D-二聚体、蛋白C活性、活化蛋白C抵抗、游离蛋白S、抗凝血酶、狼疮抗凝物、人凝血酶原片段F 1 + 2以及人凝血酶/抗凝血酶III复合物。APR与对照组相当。所有患者的自身免疫标志物均为阴性。抗链球菌溶血素滴度与对照组有显著差异。PT、TT、蛋白C活性和F 1 + 2水平与健康对照组有显著差异。PT和TT缩短、蛋白C活性降低而F 1 + 2水平升高表明我们的患者处于高凝状态。在FMF患者中检测到的高凝状态表明,通过异常凝血试验进行筛查可能有助于追踪这些患者亚临床炎症的未来后果。需要开展涵盖更大患者群体的研究来验证目前在FMF中观察到的高凝状态。